Not a member? To register
Eli Lilly and Co. (Indianapolis, Indiana) announced that it has more than doubled its investment in its production facility in Lebanon, Indiana, with a new commitment of $5. 3 billion, expanding the company’s total investment in the facility from $3. 7 billion to $9 billion. This expansion will enhance Lilly’s ability to manufacture active pharmaceutical ingredients (APIs) for the Zepbound (tirzepatide) and Mounjaro (tirzepatide) injectables.
Since 2020, Lilly has committed more than $16 billion to expand new production facilities in the U. S. New locations outside of Indiana include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany. In addition, the company has invested another $1. 2 billion to modernize existing production facilities in Indianapolis and recently acquired an injectables production facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals. Together, those production investments add up to more than $18 billion. .
“Today’s announcement represents the largest production investment in our company’s history and, in our opinion, represents the largest investment in artificial medicine API production in U. S. history,” said David A. Ricks, president and chief executive officer of Lilly. This multi-site campus will allow our newest medicines, adding Zepbound and Mounjaro, to aid portfolio expansion and leverage the newest technologies and automations for maximum efficiency, safety, and quality control. Most importantly, we are making an investment in our home state of Indiana by creating cutting-edge, high-paying production, engineering, and science jobs for many existing, long-term Hoosier families.
Lilly embarked on a significant expansion of its production in 2020, driven by the effects of tirzepatide studies. The company has jeopardized this strategic investment decision so that, following the approval of Mounjaro (2022) and Zepbound (2023), it can manufacture those drugs are available to adults living with type 2 diabetes and obesity, respectively. Since then, the mainstream demand for those drugs — the only approved remedies that activate two incretin hormone receptors, GIP and GLP-1 — underscores the pressure and unmet need for remedies for type 2 diabetes and obesity.
As a component of this additional investment at the Lebanon site, located in Indiana’s LEAP research and innovation district, Lilly plans to create two hundred full-time jobs for highly professional staff, such as engineers, scientists, operations staff and laboratory technicians, representing approximately 900 full-time staff when the facility is fully operational. In addition, more than 5,000 structural jobs will be created along the progress of the site.
“Lilly continues to play a transformative role in shaping Indiana’s opportunity economy, and I couldn’t be prouder of its leadership position in advancing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been the engine of innovation and the global economy. expansion that will be felt for decades to come here at home,” said Indiana Gov. Eric J. As a global company headquartered in Indiana, Lilly had a global range of features prior to making this investment, and opting for Indiana once back reinforces the incredible environment we have cultivated and the talented workforce we have to drive Lilly’s success. I look forward to seeing the incredible benefits this investment will bring to patients around the world, knowing they were made in Indiana. ”
For Lilly’s expansion project, the state will contribute to infrastructure solutions (roads, water, power and other utilities), as well as painting progress commitments and certain economic incentives tied to achieving the company’s investment and employment goals. , pending approval, for the structure of a learning and education center that will be part of the larger LEAP business progression, as well as a commitment to work with Lilly to raise capital for its completion. The new education center aligns with Lilly’s in the past. announced funding for education and scholarship systems with Purdue University and Ivy Tech Community College, and the BioCrossroads-led education center at 16 Tech, part of the recent Indiana Tech Hub designation.
“Lilly’s commitment to the demand for our life-changing medicines extends beyond buildings to educational opportunities and the creation of tomorrow’s global workforce,” said Edgardo Hernandez, executive vice president and president of production operations at Lilly. “Academia is a critical partner to both industry and government, as we work together to promote innovation in our state and in communities around the world.
Since beginning work on its production site in Lebanon in 2023, Lilly has remodeled a significant portion of the nearly 600-acre complex into an active structure site. The company plans to start producing medicines in Lebanon by the end of 2026, with ramping up operations until 2028.
Chemical engineering news and content published weekly